PMGC Holdings (ELAB) Non-Current Debt (2024 - 2026)
PMGC Holdings' (ELAB) quarterly Non-Current Debt came in at $85000.0 in Q1 2026, little changed quarter-over-quarter from $85000.0 in Q4 2025.
Powered by 
Analysis
PMGC Holdings (ELAB) Non-Current Debt (2024 - 2026) Analysis & Trends
PMGC Holdings has disclosed Non-Current Debt across 3 years of filings, most recently posting $85000.0 for Q1 2026.
- In Q1 2026, Non-Current Debt changed N/A year-over-year to $85000.0; the TTM figure through Mar 2026 stood at $85000.0 (changed N/A YoY), while the FY2025 annual figure was $85000.0, changed N/A from the prior year.
- Non-Current Debt came in at $85000.0 for Q1 2026 at PMGC Holdings, roughly flat from $85000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $869711.0 in Q3 2024 to a low of $85000.0 in Q4 2025.
- Average Non-Current Debt over 3 years is $477006.4, with a median of $491557.0 recorded in 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.09 Bn | 193.10 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.79 Bn | 73.79 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 61.15 Bn | 55.97 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.35 Bn | 48.21 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.40 Bn | 30.10 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.66 Bn | 30.38 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 29.14 Bn | 29.14 Bn | 1.16 Mn | - |
| 10 | PMGC Holdings | 2.25 Mn | -16.55 Mn | 385,691.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 85,000.00 |
| Dec 31, 2025 | 85,000.00 |
| Sep 30, 2024 | 869,711.00 |
| Jun 30, 2024 | 853,764.00 |
| Mar 31, 2024 | 491,557.00 |